Quantcast

Latest NeuroSigma Inc. Stories

2014-08-26 20:21:12

LOS ANGELES, Aug. 26, 2014 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles-based life sciences company established to develop bioelectronic technologies, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Jefferies LLC will act as the...

2014-08-25 08:20:30

LOS ANGELES, Aug. 25, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. Department of the Army, through the U.S. Army Medical Research and Material Command, has funded a Phase II clinical trial at the University of California, Los Angeles (UCLA), that will examine the use...

2014-07-22 08:30:55

LOS ANGELES, July 22, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) Therapy for the treatment of neurological and neuropsychiatric disorders, today announced that enrollment has begun in a pediatric open label study of external trigeminal nerve stimulation (eTNS) as adjunctive therapy for the treatment of Lennox-Gastaut Syndrome (LGS). The trial is being conducted at...

2014-07-09 08:27:34

LOS ANGELES, July 9, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded UCLA a grant that funds a Phase II 90-subject pediatric clinical trial at the University of California, Los Angeles (UCLA) focused on the treatment of...

2014-07-08 08:29:45

European Clinical Data and Mechanism of Action Results Presented LOS ANGELES, July 8, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, today announced top-line summaries of presentations made last week at the 11th European Congress on Epileptology in Stockholm, Sweden, related to the use of external...

2014-06-03 08:31:20

LOS ANGELES, June 03, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, today announced that Ian A. Cook, M.D., has joined NeuroSigma on June 1, 2014 as Chief Medical Officer and Senior Vice President. Dr. Cook is a physician and bioengineer who has been an innovator in medical therapeutics and...

2014-04-01 08:28:00

LOS ANGELES, April 1, 2014 /PRNewswire/ -- NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, today announced that it has received approval from the Therapeutic Goods Administration (TGA) to market its Monarch(TM) eTNS(TM) System in Australia. The approval allows NeuroSigma to market the Monarch eTNS System for the adjunctive...

2014-03-28 08:26:16

Carl Adams Promoted to Chief Financial Officer and Craig Rostamian Joins as Vice President of Finance LOS ANGELES, March 28, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, announced the promotion of Carl Adams to Chief Financial Officer (CFO) and the appointment of Craig Rostamian as Vice President...

2014-02-25 08:31:10

LOS ANGELES, Feb. 25, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, announced the appointment of David Hayes, Esq. as Senior Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary. Prior to joining NeuroSigma, Mr. Hayes was a partner at Hayes and Boone, LLP, since...

2014-02-11 08:30:26

LOS ANGELES, Feb. 11, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, announced the appointment of Carl Adams as Vice President and Controller. Mr. Adams brings 20 years of experience in accounting and corporate finance to NeuroSigma. After nine years at Ernst and Young LLP, culminating as a...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related